ValoreQ4, 24Q4, 25TTMSpese di vendita, generali e amministrative———Ricerca e sviluppo———Reddito operativo———Proventi non operativi, Totale———Oneri finanziari, al netto degli interessi capitalizzati———Proventi non operativi, esclusi gli oneri finanziari———Entrate/uscite straordinarie———Utile al lordo delle imposte———Quota di utile———Imposte———Interessi di minoranza———Altri proventi/oneri al netto delle imposte———Utile netto al lordo delle attività cessate———Attività cessate———Utile netto———Regolazione della diluizione———Dividendi privilegiati———Utile netto diluito attribuibile agli azionisti ordinari———Utile base per azione (EPS base)———Utile diluito per azione (EPS diluito)———Numero medio di azioni ordinarie in circolazione———Azioni diluite in circolazione———EBITDA———EBIT———Costo del fatturato———Altri costi del venduto———Ammortamento e svalutazione (liquidità)———
Sanofi - American Depositary Shares
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company trades as "SAN" on Euronext Paris and "SNY" on Nasdaq in the United States, and is a component of the Euro Stoxx 50 stock market index. In 2023, the company’s seat in the Forbes Global 2000 was 89.
Sanofi engages in the research and development, manufacturing, and marketing of pharmacological products, principally in the prescription market, but the firm also develops over-the-counter medications. The corporation covers seven major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis, and vaccines. It is the world's largest producer of vaccines through its subsidiary Sanofi Pasteur.